Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

Rajen Mody(C. S. Mott Children's Hospital), Arlene Naranjo(University of Florida), Collin Van Ryn(University of Florida), Alice L. Yu(Chang Gung University), Wendy B. London(Dana-Farber Cancer Institute), Barry L. Shulkin(St. Jude Children's Research Hospital), Marguerite T. Parisi(University of Washington), Sabah-E-Noor Servaes(Children's Hospital of Philadelphia), Mitchell B. Diccianni(University of California, San Diego), Paul M. Sondel(University of Wisconsin–Madison), Julia Glade Bender(Columbia University Irving Medical Center), John M. Maris(Children's Hospital of Philadelphia), Julie R. Park(University of Washington), Rochelle Bagatell(Children's Hospital of Philadelphia)
The Lancet Oncology
May 23, 2017
Cited by 273Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis